Home › Trials › NCT06005428
Clinical trial No longer in our active list Phase 2 Interventional Ages 18 to 99

Evaluating CRD-4730 for treating Catecholaminergic Polymorphic Ventricular Tachycardia

Official title: A Phase 2A, Investigator & Subject Blinded, Sponsor Unblinded, Placebo-Controlled, Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of CRD-4730 in Participants with Catecholaminergic Polymorphic Ventricular Tachycardia

Run by Cardurion Pharmaceuticals, Inc. · NCT06005428 · Data updated 2026-05-14

This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.

This study is testing a new drug called CRD-4730 to see if it can help adults with Catecholaminergic Polymorphic Ventricular Tachycardia manage their symptoms better.

Quick facts

PhasePhase 2
Study typeInterventional
Ages18 Years to 99 Years
SexAll
Enrollment12 (estimated)
SponsorCardurion Pharmaceuticals, Inc.
Industry-sponsored
Locations11 sites (Cincinnati, Ohio and 10 other locations)
Trial IDNCT06005428 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18 and older with a confirmed diagnosis of CPVT based on genetic screening.

Probably not a fit

Patients with clinically significant structural heart disease or recent history of myocardial infarction may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2 clinical trial investigates the safety, tolerability, pharmacokinetics, and pharmacodynamics of CRD-4730 in adults diagnosed with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). Participants will be randomly assigned to receive two different doses of CRD-4730 and a placebo in a double-blind manner. The study aims to assess the drug's effectiveness in managing symptoms associated with CPVT through a multicenter approach. Each participant will undergo a series of evaluations to monitor their response to the treatment.

Why it matters

Potential benefit: If successful, this treatment could significantly improve the management of CPVT, reducing the risk of life-threatening arrhythmias.

How similar studies have gone: While there have been studies on CPVT treatments, the specific approach using CRD-4730 is novel and has not been extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. Males or Females ≥18 years of age, at screening.
2. Confirmed CPVT diagnosis, based on genetic screening for a known RyR2 mutation and a clinical phenotype consistent with CPVT at screening.
3. The participant can perform an EST during which frequent premature ventricular contraction (PVCs) (≥10 per minute), ventricular bigeminy, or higher-grade VA (equivalent to a VA score ≥2) are identified by the investigator.
4. Stable doses of any anti-arrhythmic medication, except amiodarone, for 4 weeks prior to screening.
5. Adhere to all contraceptive criteria.

Exclusion Criteria:

1. Clinically significant structural heart disease, diagnosis of heart failure, or clinically significant coronary artery disease.
2. History of a myocardial infarction, cerebrovascular accident, or transient ischemic attack within 3 months of screening.
3. History of malignancy within the past 5 years at screening (except successfully treated basal cell carcinoma or non-metastatic squamous cell carcinoma of the skin or cervical carcinoma in situ).
4. Female participant that is pregnant or lactating/ breastfeeding, or has plans to do so during the study or within 3 months following last dose of study drug.
5. Use of amiodarone with 3 months prior to screening. NOTE: other protocol defined Inclusion/ Exclusion criteria may apply.

Where it's running

  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio, United States     Recruiting
  • Cleveland Clinic Children's Hospital
    Cleveland, Ohio, United States     Recruiting
  • Baylor College of Medicine
    Houston, Texas, United States     Recruiting
  • Stollery Children's Hospital University of Alberta
    Edmonton, Alberta, Canada     Recruiting
  • University of British Columbia (UBC) Hospital
    Vancouver, British Columbia, Canada     Recruiting
  • British Columbia Children's Hospital
    Vancouver, British Columbia, Canada     Recruiting
Show 5 more locations
  • University of Western Ontario
    London, Ontario, Canada     Recruiting
  • Hôptal Nord Laennec
    Nantes, Loire-Atlantique, France     Recruiting
  • Hôpital Louis Pradel
    Bron, France     Recruiting
  • Groupe Hospitalier Bichat Claude Bernard
    Paris, France     Recruiting
  • IRCCS Pavia Istituti Clinici Scientifici Maugeri Spa Società Benefit
    Pavia, Lombardia, Italy     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Heart Defects, Congenital 8Heart Diseases 60Ventricular Tachycardia 59Cardurion Pharmaceuticals, Inc. 2
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.